Remedying dysfunctional angiogenesis and tissue ischemia with Barleria lupulina

用羽扇豆芽孢杆菌治疗功能失调的血管生成和组织缺血

基本信息

  • 批准号:
    8619588
  • 负责人:
  • 金额:
    $ 47.55万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2012
  • 资助国家:
    美国
  • 起止时间:
    2012-03-01 至 2016-02-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Tissue ischemia, defined as insufficient blood flow for providing oxygen and nutrients, is a serious clinical problem associated with aging, diabetes, hypercholesterolemia, and obesity. Ischemia results from progressive functional decline of large and small blood vessels and the consequences are debilitating and often fatal. The specific objectives of the proposed research plan are to identify effective, mechanistically characterized strategies, employing natural products, for overcoming current barriers to alleviation of ischemia. The specific aims are: (Aim 1a) Investigate oral administration of aqueous extracts of Barleria lupulina (AE-BL) for remedying ischemia-driven dysfunctional angiogenesis in mouse models, and define benefits for tissue oxygenation and survival; (Aim 1b) Define cellular and molecular mechanisms; (Aim 2a) Identify the individual components constituting the full activity of un-fractionated AE-BL, which stabilize the endothelial cell (EC) cytoskeleton and EC-EC junctions; (Aim 2b) Indentify combinations of purified components that remedy dysfunctional, ischemia-driven angiogenesis similarly to the un-fractionated extract. The specific vascular improvements (e.g., vessel architecture, lumen formation, network integration, barrier integrity, blood flow) provided by oral administration of AE-BL, and the resulting improvement in tissue oxygenation and tissue survival will be defined in mouse models of ischemia-driven angiogenesis. EC signaling pathways and cytoskeleton-regulating mechanisms through which AE-BL remedies dysfunctional vascular morphogenesis and thereby improves angiogenesis will be defined with ECs in vitro. These in vitro assays also will be employed to identify purified components of AE-BL with important bioactivity and to identify combinations of purified components comprising bioactivity similar to un-fractionated AE-BL. Thus, the proposed research plan is designed to illustrate a new strategy for remedying dysfunctional angiogenesis and alleviating tissue ischemia with un-fractionated AE-BL and also to identify specific compounds that embody this important biological activity.
描述(由申请人提供):组织缺血,定义为提供氧气和营养的血流不足,是与衰老、糖尿病、高胆固醇血症和肥胖相关的严重临床问题。缺血是由大小血管的进行性功能衰退引起的,其后果是使人衰弱且通常是致命的。拟议的研究计划的具体目标是确定有效的,机械特征的策略,采用天然产品,克服目前的障碍,以减轻缺血。具体目标是:(目的1a)在小鼠模型中研究口服啤酒花水提取物(AE-BL)对缺血驱动的功能障碍性血管生成的补救作用,并确定对组织氧合和存活的益处;(目的1b)确定细胞和分子机制;(目的2a)鉴定构成未分级AE-BL的全部活性的各个组分,其稳定内皮细胞(EC)细胞骨架和EC-EC连接;(目的2b)鉴定纯化组分的组合,其类似于未分级提取物治疗功能障碍的缺血驱动的血管生成。具体的血管改善(例如,血管结构、管腔形成、网络整合、屏障完整性、血流),以及由此产生的组织氧合和组织存活的改善将在局部缺血驱动的血管生成的小鼠模型中定义。EC信号通路和细胞因子调节机制,通过AE-BL补救功能障碍的血管形态发生,从而改善血管生成将在体外与EC定义。这些体外测定也将用于鉴定具有重要生物活性的AE-BL的纯化组分,并鉴定包含与未分级AE-BL相似的生物活性的纯化组分的组合。因此,拟议的研究计划旨在说明一种新的策略,用于补救功能失调的血管生成和减轻组织缺血与未分级AE-BL,并确定具体的化合物,体现了这一重要的生物活性。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DONALD R SENGER其他文献

DONALD R SENGER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DONALD R SENGER', 18)}}的其他基金

Remedying dysfunctional angiogenesis and tissue ischemia with Barleria lupulina
用羽扇豆芽孢杆菌治疗功能失调的血管生成和组织缺血
  • 批准号:
    8232766
  • 财政年份:
    2012
  • 资助金额:
    $ 47.55万
  • 项目类别:
Remedying dysfunctional angiogenesis and tissue ischemia with Barleria lupulina
用羽扇豆芽孢杆菌治疗功能失调的血管生成和组织缺血
  • 批准号:
    8432035
  • 财政年份:
    2012
  • 资助金额:
    $ 47.55万
  • 项目类别:
Regulation of Vascular Morphogenesis in Adult Brain
成人大脑血管形态发生的调节
  • 批准号:
    7864039
  • 财政年份:
    2009
  • 资助金额:
    $ 47.55万
  • 项目类别:
Rectifying defects in tumor vasculature to improve chemo- and radiation therapies
纠正肿瘤血管系统缺陷以改善化疗和放射治疗
  • 批准号:
    7585251
  • 财政年份:
    2008
  • 资助金额:
    $ 47.55万
  • 项目类别:
Rectifying defects in tumor vasculature to improve chemo- and radiation therapies
纠正肿瘤血管系统缺陷以改善化疗和放射治疗
  • 批准号:
    8212118
  • 财政年份:
    2008
  • 资助金额:
    $ 47.55万
  • 项目类别:
Rectifying defects in tumor vasculature to improve chemo- and radiation therapies
纠正肿瘤血管系统缺陷以改善化疗和放射治疗
  • 批准号:
    7766926
  • 财政年份:
    2008
  • 资助金额:
    $ 47.55万
  • 项目类别:
Rectifying defects in tumor vasculature to improve chemo- and radiation therapies
纠正肿瘤血管系统缺陷以改善化疗和放射治疗
  • 批准号:
    7465105
  • 财政年份:
    2008
  • 资助金额:
    $ 47.55万
  • 项目类别:
Rectifying defects in tumor vasculature to improve chemo- and radiation therapies
纠正肿瘤血管系统缺陷以改善化疗和放射治疗
  • 批准号:
    8018502
  • 财政年份:
    2008
  • 资助金额:
    $ 47.55万
  • 项目类别:
BETA 1 INTEGRIN ANTAGONISM & RETINAL NEOVASCULARIZATION
Beta 1 整合素拮抗作用
  • 批准号:
    6044591
  • 财政年份:
    2000
  • 资助金额:
    $ 47.55万
  • 项目类别:
BETA 1 INTEGRIN ANTAGONISM & RETINAL NEOVASCULARIZATION
Beta 1 整合素拮抗作用
  • 批准号:
    6350899
  • 财政年份:
    2000
  • 资助金额:
    $ 47.55万
  • 项目类别:

相似海外基金

Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
  • 批准号:
    495182
  • 财政年份:
    2023
  • 资助金额:
    $ 47.55万
  • 项目类别:
Parkinson's disease and aging affect neural activation during continuous gait alterations to the split-belt treadmill: An [18F] FDG PET Study.
帕金森病和衰老会影响分体带跑步机连续步态改变期间的神经激活:[18F] FDG PET 研究。
  • 批准号:
    400097
  • 财政年份:
    2019
  • 资助金额:
    $ 47.55万
  • 项目类别:
The elucidation of the mechanism by which intestinal epithelial cells affect impaired glucose tolerance during aging
阐明衰老过程中肠上皮细胞影响糖耐量受损的机制
  • 批准号:
    19K09017
  • 财政年份:
    2019
  • 资助金额:
    $ 47.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Does aging of osteocytes adversely affect bone metabolism?
骨细胞老化会对骨代谢产生不利影响吗?
  • 批准号:
    18K09531
  • 财政年份:
    2018
  • 资助金额:
    $ 47.55万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Links between affect, executive function, and prefrontal structure in aging: A longitudinal analysis
衰老过程中情感、执行功能和前额叶结构之间的联系:纵向分析
  • 批准号:
    9766994
  • 财政年份:
    2018
  • 资助金额:
    $ 47.55万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9320090
  • 财政年份:
    2017
  • 资助金额:
    $ 47.55万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    10166936
  • 财政年份:
    2017
  • 资助金额:
    $ 47.55万
  • 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
  • 批准号:
    9761593
  • 财政年份:
    2017
  • 资助金额:
    $ 47.55万
  • 项目类别:
Experimental Model of Depression in Aging: Insomnia, Inflammation, and Affect Mechanisms
衰老过程中抑郁症的实验模型:失眠、炎症和影响机制
  • 批准号:
    9925164
  • 财政年份:
    2016
  • 资助金额:
    $ 47.55万
  • 项目类别:
Experimental Model of Depression in Aging: Insomnia, Inflammation, and Affect Mechanisms
衰老过程中抑郁症的实验模型:失眠、炎症和影响机制
  • 批准号:
    9345997
  • 财政年份:
    2016
  • 资助金额:
    $ 47.55万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了